this compound maleate

AZD9496 maleate is a highly potent and selective antagonist of the estrogen receptor alpha (ERα), exhibiting an IC50 value of 0.28 nM. This compound, AZD9496 maleate, is an orally bioavailable selective estrogen receptor degrader (SERD).

Zetomipzomib maleate (KZR-616), a novel immunoproteasome inhibitor, effectively and selectively inhibits the LMP7 subunit (hLMP7 mLMP7 IC50: 39 57 nM) and LMP2 subunit (hLMP7 mLMP7 IC50: 131 179 nM) of the immunoproteasome. This compound shows promising potential for research in various autoimmune diseases.

CDK4 6-IN-21 maleate (compound I-52) is a potent inhibitor of CDK4 and CDK6, with IC50 values of 3.88 nM and 3.31 nM, respectively. This compound exhibits antitumor activity.

Sutetinib maleate is the maleate salt form of Sutetinib. This compound functions as an orally effective tyrosine kinase (tyrosine kinase) inhibitor that targets tyrosine kinases associated with tumor growth and angiogenesis, including VEGFR (VEGFR-1 2 3 with Ki=0.009 µM), PDGFR (PDGFR-α β with Ki=0.008 µM), and the proto-oncogene cKIT. Sutetinib maleate inhibits the proliferation, migration, and tubular structure formation of endothelial and fibroblast cells, displaying antitumor activity across various tumor cell lines.